# Sermorelin vs Ipamorelin: GHRH Analog vs Ghrelin-Receptor Secretagogue > Sermorelin vs ipamorelin: sermorelin is a GHRH analog acting at the GHRH receptor; ipamorelin is a growth-hormone-releasing peptide acting at the ghrelin/GHS receptor — two routes to the same GH output. Two compounds, two different receptors, one shared pituitary output. The mechanism contrast, drawn as exposed structure. ## The short version Put simply, **sermorelin vs ipamorelin** is a contrast of two doors into the same room. Sermorelin is a GHRH analog — it presses the GHRH receptor, the pituitary's natural growth-hormone trigger. Ipamorelin is a growth-hormone-releasing peptide that presses a different button, the ghrelin (GHS) receptor — the same receptor the hunger hormone uses. Both end up telling the pituitary to release growth hormone, but they take separate signaling routes to get there. This page compares the two by mechanism and by what each has actually been studied for, without recommending either. ## Sermorelin vs ipamorelin: what is the difference? Sermorelin is a GHRH analog acting at the GHRH receptor; ipamorelin is a growth-hormone-releasing peptide acting at the ghrelin/GHS receptor — two different receptors and signaling routes to the same pituitary growth-hormone output [11]. Sermorelin replicates the hypothalamic GHRH signal; ipamorelin mimics ghrelin's action on the somatotroph. The convergent endpoint is growth-hormone release, reached by distinct upstream mechanisms. ## Two receptors, one output The cleanest way to hold the comparison is by receptor. Sermorelin binds the GHRH receptor (GHRH-R), a class B G-protein-coupled receptor on pituitary somatotrophs, and drives the adenylate cyclase / cAMP / PKA pathway [11]. Ipamorelin belongs to the growth-hormone-releasing peptide (GHRP) class, which acts on the ghrelin / growth-hormone-secretagogue receptor (GHS-R) — the receptor for the stomach-derived hormone ghrelin — a mechanism entirely separate from the GHRH pathway [11]. Both ultimately prompt the somatotroph to release growth hormone, which is why they are often discussed together and sometimes studied as complementary inputs in the broader secretagogue literature [11]. But they are not interchangeable: they engage different receptors, different intracellular signals, and different points in the body's regulation of growth hormone. Sermorelin carries the more substantial human clinical history of the two — a former pediatric approval and adult GH-axis and cognition research [1][2][6] — which is the reading this site documents in [the GHRH(1-29) research record](/research). ## Why the receptor difference matters The two receptors do not merely sit in different places — they answer to different parts of the body's physiology, and that shapes what each compound does and does not override. The GHRH receptor is the pituitary's dedicated growth-hormone trigger, the cell-surface partner for the hypothalamic GHRH signal; pressing it with sermorelin reproduces a signal the somatotroph is built to receive [11]. The ghrelin / GHS receptor is the partner for ghrelin, a hormone better known for appetite, and growth-hormone-releasing peptides like ipamorelin borrow that pathway to reach the same somatotroph by a side door [11]. This matters for how the body's controls respond. Because sermorelin works through the native GHRH route, the opposing somatostatin brake and IGF-1 feedback remain squarely in the loop, holding the growth-hormone rise within physiologic bounds [13][2]. The GHS-receptor route engages a partly different regulatory context. The shared endpoint — a growth-hormone pulse from the pituitary — can look similar from the outside, but the upstream biology is not the same, which is the entire reason "two receptors, one output" is the honest summary rather than "two names for the same thing." A practical consequence is that the two are sometimes discussed as complementary inputs in the broader secretagogue literature, precisely because they are mechanistically distinct [11]. That is a research observation about pathways, not an endorsement of combining them. ## How the comparison maps to the evidence On the sermorelin side, the human record is concrete: accelerated growth in deficient children [1], restored 24-hour growth hormone and IGF-1 in older men [2], and a favorable cognition signal for the GHRH analog class [6]. Sermorelin also carries a regulatory history — a former pediatric FDA approval, withdrawn from the US market in 2008 for commercial reasons, and present-day compounding status [5]. The shared limitation is that broad adult anti-aging efficacy for growth-hormone secretagogues — sermorelin and ipamorelin alike — is not established, and the Annals editorial's "not yet ready for prime time" caution applies to the secretagogue strategy as a whole [5]. A further mechanistic point favors caution against over-stacking: both compounds aim at the same pituitary output, so combining them does not multiply distinct mechanisms — it doubles up on a single regulated endpoint that the body's somatostatin and IGF-1 feedback still governs [13]. Reading either compound onto the other's data is also a mistake the literature does not support: the concrete human findings on this page belong to sermorelin (and, for cognition and body composition, to the related GHRH analog tesamorelin) [6], not to ipamorelin. This is mechanism and evidence-mapping, not a protocol; this site does not recommend either compound or any combination, and points readers to [the GHRH(1-29) research record](/research) and [sermorelin side effects](/side-effects) for the full reading. --- A constructivist reading board for the sermorelin record — every GHRH(1-29) figure logged to its study and the empty long-term adult-evidence members left openly unfilled; sermorelin was a medicine, is read here as research, and nothing on this board is dispensed, prescribed, or sold.